No Data
No Data
Eli Lilly's Stock on Pace for Record Close as Crohn's Disease Trial Hits the Mark
By Eleanor Laise Drugmaker also set to collaborate on new cancer treatments Eli Lilly & Co. (LLY) shares were on pace for a record closing high Tuesday after the drugmaker released data from a late-
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
The Structure Therapeutics (NASDAQ:GPCR) stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential.What Happened: JPMorgan
Top Gap Ups and Downs on Tuesday: LLY, AZN, NTES and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Health Care Up as Eli Lilly Hits Record High - Health Care Roundup
Health-care companies rose as traders continued to pile into obesity-drug makers. Eli Lilly shares tested record highs after the drugmaker released data from a late-stage Crohn's disease trial and st
JPM Lists Stocks With the Least Price Swings, Most Attractive Option-sale Candidates
Eli Lilly and Co Options Spot-On: On May 21st, 61,424 Contracts Were Traded, With 236.98K Open Interest
On May 21st ET, $Eli Lilly and Co(LLY.US)$ had active options trading, with a total trading volume of 61,424 options for the day, of which put options accounted for 26.44% of the total transactions, a
No Data